SecSonar.com

Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Dianthus Therapeutics, Inc. (DNTH) is a Biotechnology company based in US with a market capitalization of $3.8B. Revenue declined 67.3% year-over-year and free cash flow was negative at -$129.3M. This page tracks DNTH's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 78 employees · IPO Jun 21, 2018

Valuation

Valuation & price

$86.16 · as of May 17, 2026 · -11.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.76

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$95.76$57.01$18.25Jul 25Dec 25Jul 26Jul 7, 25$18.25Jul 9, 25$21.09Jul 11, 25$20.06Jul 15, 25$19.04Jul 17, 25$20.35Jul 21, 25$20.74Jul 23, 25$22.10Jul 25, 25$21.50Jul 29, 25$21.39Jul 31, 25$20.67Aug 4, 25$21.50Aug 6, 25$20.39Aug 11, 25$18.89Aug 13, 25$20.85Aug 15, 25$20.74Aug 19, 25$22.70Aug 21, 25$23.65Aug 25, 25$23.41Aug 27, 25$24.24Aug 29, 25$23.57Sep 3, 25$24.26Sep 5, 25$26.50Sep 9, 25$35.57Sep 11, 25$37.86Sep 16, 25$37.47Sep 18, 25$38.87Sep 22, 25$37.76Sep 24, 25$37.19Sep 26, 25$36.71Sep 30, 25$39.35Oct 2, 25$36.93Oct 6, 25$34.46Oct 8, 25$34.75Oct 10, 25$34.46Oct 14, 25$35.55Oct 16, 25$36.00Oct 21, 25$35.03Oct 23, 25$33.27Oct 27, 25$33.52Oct 29, 25$33.82Oct 31, 25$34.98Nov 4, 25$33.20Nov 6, 25$36.43Nov 10, 25$36.61Nov 12, 25$38.72Nov 14, 25$40.85Nov 18, 25$40.82Nov 20, 25$40.39Nov 25, 25$44.09Nov 28, 25$43.98Dec 2, 25$42.28Dec 4, 25$44.71Dec 8, 25$43.60Dec 10, 25$43.58Dec 12, 25$42.13Dec 16, 25$41.40Dec 18, 25$41.75Dec 22, 25$43.77Dec 24, 25$43.15Dec 29, 25$41.62Jan 2, 26$39.68Jan 6, 26$36.20Jan 8, 26$38.12Jan 12, 26$39.12Jan 14, 26$46.29Jan 16, 26$44.10Jan 21, 26$48.03Jan 23, 26$52.33Jan 27, 26$50.31Jan 29, 26$53.36Feb 2, 26$53.18Feb 4, 26$48.13Feb 9, 26$52.71Feb 11, 26$49.92Feb 13, 26$47.40Feb 18, 26$47.47Feb 20, 26$49.56Feb 24, 26$52.86Feb 26, 26$53.11Mar 2, 26$55.26Mar 4, 26$62.03Mar 6, 26$65.20Mar 10, 26$86.92Mar 12, 26$80.32Mar 17, 26$78.90Mar 19, 26$80.00Mar 23, 26$79.32Mar 25, 26$79.61Mar 27, 26$81.13Mar 31, 26$83.92Apr 2, 26$86.00Apr 7, 26$86.20Apr 9, 26$91.66Apr 13, 26$90.00Apr 15, 26$95.76Apr 17, 26$93.26Apr 22, 26$91.29Apr 24, 26$87.39Apr 28, 26$83.67Apr 30, 26$87.80May 4, 26$89.34May 6, 26$90.42May 8, 26$86.71May 12, 26$86.15May 14, 26$85.34May 18, 26$83.60May 20, 26$88.72May 22, 26$86.48May 28, 26$90.86Jun 1, 26$89.45Jun 3, 26$84.97Jun 5, 26$80.51Jun 9, 26$84.57Jun 11, 26$76.45Jun 15, 26$82.51Jun 17, 26$81.89Jun 22, 26$87.37Jun 24, 26$90.80Jun 26, 26$95.35Jul 2, 26$94.34
$18.2552-week range$97.48
Loading valuation history…

Fundamentals

Key fundamentals

$3.8B

Market cap

-67.3%

Revenue growth (YoY)

100.0%

Gross margin

-$129.3M

Free cash flow (USD)

-$402.9M

Net debt

Net cash position

13.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$1.5MFY 2022$6.4MFY 2023$2.8MFY 2024$6.2MFY 2025$2.0M
$0$2M

Free cash flow by year

2016 → 2025

FY 2016$-6.7MFY 2017$-24.5MFY 2018$-49.6MFY 2019$-60.2MFY 2020$-64.4MFY 2021$-60.8MFY 2022$-29.2MFY 2023$-37.0MFY 2024$-78.3MFY 2025$-129.3M
-$6.7M-$129.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

4

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $2.4M · 10b5-1 PlanVeness Adam M · SVP, General Counsel and Sec. · $2.4MJun 18, 2026Filing
  • 8-K eventPipeline UpdateJun 12, 2026Filing
  • Insider sellInsider Sell $2.4M · 10b5-1 PlanRandhawa Simrat · EVP, Head of R&D · $2.4MJun 2, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 22, 2026Filing
  • Insider sellInsider Sell $51K · 10b5-1 PlanSoteropoulos Paula · Director · $51.2KMay 11, 2026Filing
  • 8-K eventQ1 2026 Financial ResultsMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • Insider sellInsider Sell $739K · 10b5-1 PlanSavitz Ryan · EVP, CFO & CBO · $738.8KApr 10, 2026Filing
  • Insider sellInsider Sell $48K · 10b5-1 PlanSoteropoulos Paula · Director · $48KApr 1, 2026Filing
  • Insider sellInsider Sell $9.5M · 10b5-1 PlanSavitz Ryan · EVP, CFO & CBO · $9.5MApr 1, 2026Filing

Questions

Frequently asked questions

What is Dianthus Therapeutics, Inc.'s market cap?

Dianthus Therapeutics, Inc. (DNTH) has a market capitalization of $3.8B.

What is DNTH's P/E ratio?

A meaningful P/E ratio is not available for DNTH — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is DNTH's price-to-book (P/B) ratio?

DNTH trades at 7.76 times book value per share.

Are insiders buying DNTH stock?

SEC Form 4 filings show no open-market insider buys at Dianthus Therapeutics, Inc. in the last 90 days (4 sells).

Same arena

Related companies in Biotechnology

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

VCYT

Veracyte, Inc.

$3.8B

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.